U.S. Anesthesia Partners, a Dallas‑based anesthesia provider backed by Welsh Carson and Berkshire Partners, reached a settlement with the Federal Trade Commission after accusations of a decade‑long scheme to consolidate anesthesia businesses in Texas for the first time.

The FTC alleged that the company’s acquisitions drove up anesthesia fees, squeezing hospitals and patients. By buying out rivals over ten years, the firm allegedly tightened pricing power across the state, a practice that drew regulatory scrutiny amid rising healthcare costs in the U.S. market.

The settlement, while not publicly quantified, signals a growing willingness by the FTC to pursue private‑equity‑backed firms that dominate niche medical markets. Investors will watch whether the deal triggers tighter oversight of similar consolidation strategies across the health‑care sector for all healthcare providers nationwide.

For patients, the settlement could translate into more competitive pricing for anesthesia services in Texas. Hospital administrators will likely reassess their vendor contracts, while the private‑equity owners may seek to diversify beyond Dallas‑centric operations to protect market share amid increasing regulatory pressure across the nation.